NeoGenomics (NEO) investor relations material

Leadership insights and operational improvements

• Greater alignment between commercial and R&D teams has accelerated product development and innovation, with notable launches such as PanTracer and RaDaR ST in the past 12–18 months.

• Earlier investments in growth opportunities could have yielded faster results, but recent operational improvements have enhanced turnaround times and efficiency.

• The organization has built a strong and growing talent base, embracing new ideas and driving performance.

Financial guidance and growth strategy

• Guidance philosophy emphasizes high confidence in meeting targets, focusing on profitable growth and prudent capital allocation, especially in sales, R&D, and IT infrastructure.

• Clinical revenue grew 15% in 2025, with 12% from volume and 3% from AUP; mid-single-digit growth in both metrics is expected for 2026, excluding the impact of low-value contracts.

• Adjusted EBITDA is projected to expand by 100 basis points in 2026, with further margin expansion anticipated as new products mature in 2027–2028.

Product and market dynamics

• Exiting a high-volume, low-value contract is expected to cause a temporary volume decline in Q1, with sequential growth resuming in Q2 and beyond.

• AUP growth is expected to remain a tailwind for several years, driven by pricing initiatives, payer coverage, and a shift to higher-value tests.

• NGS volumes represent 9–10% of total volume and a third of revenue, growing at 22–23%, with no slowdown anticipated in 2026.